955932-47-5

Basic information

• Product Name: 4-[(5-bromo-6-methyl-2-pyridinyl)oxy]-2-methyl-2-Butanol
• Synonyms: 4-[(5-bromo-6-methyl-2-pyridinyl)oxy]-2-methyl-2-Butanol
• CAS NO: 955932-47-5
• Molecular Formula: C11H16BrNO2
• Molecular Weight: 274.15424
• Mol File: 955932-47-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-[(5-bromo-6-methyl-2-pyridinyl)oxy]-2-methyl-2-Butanol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(5-bromo-6-methyl-2-pyridinyl)oxy]-2-methyl-2-Butanol(955932-47-5)
• EPA Substance Registry System: 4-[(5-bromo-6-methyl-2-pyridinyl)oxy]-2-methyl-2-Butanol(955932-47-5)

Safety Data

• Hazardous Substances Data: 955932-47-5(Hazardous Substances Data)

Upstream product

• 54923-31-8 5-bromo-6-methyl-1,2-dihydropyridin-2-one 
• 17689-66-6 3-hydroxy-3-methylbutyl toluene-4-sulfonate 
• 54923-31-8 5-bromo-2-hydroxy-6-methylpyridine 
• 2568-33-4 3-methyl-butane-1,3-diol 
• 375368-83-5 3-bromo-6-fluoro-2-methyl-pyridine 

Downstream Products

• 1312788-27-4 3-hydroxy-5-(4-(((R)-4-(6-(3-hydroxy-3-methylbutoxy)-2-methylpyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)isothiazole 1-oxide 
• 1312789-74-4 4-[5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-6-methylpyridin-2-yl]oxy-2-methylbutan-2-ol 
• 1544739-50-5 (5aR,6S,6aS)-ethyl 3-((3-(6-(3-hydroxy-3-methylbutoxy)-2-methylpyridin-3-yl)benzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 

Relevant articles and documents

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

CYCLIC AMIDE DERIVATIVE

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR7—; J1 is —CR11aR11b— or —NR11c—; J2 is —CR12aR12b— or —NR12c—; and R1 to R12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.

NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH2—, O, —S(O)i— (i is 0 to 2), or —NR7—; R1 to R6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.